Lansoprazolo Sandoz Bv (Lansoprazole)

Lansoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway, providing relief in several acid‑related conditions.

• Gastroesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by lowering stomach acid.
• Peptic ulcer disease: promotes ulcer healing and prevents recurrence by suppressing acid.
• Helicobacter pylori eradication regimen: enhances antibiotic effectiveness when combined in triple or quadruple therapy.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

• Lansoprazole irreversibly binds to the H+/K+ ATPase enzyme (the proton pump) located on gastric parietal cells. By inhibiting this final step of acid secretion, it markedly reduces the volume and acidity of gastric juice, thereby allowing damaged mucosa to heal and preventing further acid‑related injury.

Adverse reactions may occur with lansoprazole use and are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often transient.
• Diarrhea: loose stools that may resolve with continued therapy.
• Nausea: feeling of stomach upset or queasiness.
• Abdominal pain: discomfort or cramping in the stomach area.
• Flatulence: increased gas production.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Clostridioides difficile infection: persistent diarrhea with possible fever.
• Low magnesium levels: muscle cramps, irregular heartbeat, or seizures.
• Bone fractures: increased risk with long‑term use, especially in the elderly.
• Liver enzyme elevation: abnormal blood tests indicating hepatic stress.
• Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

Before initiating therapy, consider the following safety measures.

• Assess renal function: adjust use in severe impairment.
• Evaluate hepatic status: monitor if liver disease is present.
• Review long‑term use: weigh benefits against risk of fractures and nutrient deficiencies.
• Avoid abrupt discontinuation: taper if therapy has been prolonged to reduce rebound acid hypersecretion.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Lansoprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Antifungal agents (e.g., ketoconazole, itraconazole): reduced absorption and efficacy.
• HIV protease inhibitors (e.g., atazanavir): markedly decreased plasma levels.
• Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, requiring closer coagulation monitoring.
• Methotrexate (high dose): possible accumulation, monitor renal function.
• Digoxin: modest rise in serum concentrations, observe for toxicity signs.